| Print
KNIGHT THERAPEUTICS INC (GUD)
EquityThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products,consumer health products, and medical devices in Canada, Latin America and select international markets . The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships inthe life sciences industry, and to secure product distribution rights. Geographically the company generates revenue from Brazil, Colombia, Argentina, Rest of LATAM, Canada, and Other, with the majority revenue generated from the Brazil region.
Address
6111 Royalmount Avenue
Suite 102
Montréal
QC
CAN
H4P 2T4
Forecast key dates
| Name | Key Date |
|---|---|
| Knight Therapeutics Inc Third Quarter Earnings Conference Call for 2026 | 2026-11-06T08:30:00 |
| Knight Therapeutics Inc Third Quarter Earnings Results for 2026 | 2026-11-06T00:00:00 |
| Knight Therapeutics Inc Second Quarter Earnings Conference Call for 2026 | 2026-08-07T08:30:00 |
| Knight Therapeutics Inc Second Quarter Earnings Results for 2026 | 2026-08-07T00:00:00 |
| Knight Therapeutics Inc First Quarter Earnings Conference Call for 2026 | 2026-05-08T08:30:00 |
| Knight Therapeutics Inc First Quarter Earnings Results for 2026 | 2026-05-08T00:00:00 |
| Knight Therapeutics Inc Annual General Meeting for 2026 | 2026-05-07T00:00:00 |
| Knight Therapeutics Inc Fourth Quarter Earnings Conference Call for 2025 | 2026-03-20T08:30:00 |
| Knight Therapeutics Inc Fourth Quarter Earnings Results for 2025 | 2026-03-20T00:00:00 |
| Knight Therapeutics Inc Annual Report for 2025 | 2026-03-20T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Knight Therapeutics Inc Third Quarter Earnings Conference Call for 2025 | 2025-11-06T08:30:00 |
| Knight Therapeutics Inc Third Quarter Earnings Result for 2025 | 2025-11-06T00:00:00 |
| Knight Therapeutics Inc Second Quarter Earnings Conference Call for 2025 | 2025-08-07T08:30:00 |
| Knight Therapeutics Inc Second Quarter Earnings Results for 2025 | 2025-08-07T00:00:00 |
| Knight Therapeutics Inc First Quarter Earnings Conference Call for 2025 | 2025-05-08T08:30:00 |
| Knight Therapeutics Inc First Quarter Earnings Results for 2025 | 2025-05-08T00:00:00 |
| Knight Therapeutics Inc Annual General Meeting for 2025 | 2025-05-07T00:00:00 |
| Knight Therapeutics Inc Fourth Quarter Earnings Conference Call for 2024 | 2025-03-20T08:30:00 |
| Knight Therapeutics Inc Fourth Quarter Earnings Result for 2024 | 2025-03-20T00:00:00 |
| Knight Therapeutics Inc Annual Report for 2024 | 2025-03-20T00:00:00 |
| Knight Therapeutics - Conference Call | 2025-03-11T08:30:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.